gibreel ferishta's personal annotations on this page
Gibreel bookmarked
on 2009-08-27
Expanding the scope of India’s current patent regime to include incremental pharma innovation would benefit the domestic pharma players, according to a study commissioned by the US India Business Council, which was released on Wednesday.
Citing statistics from the National Knowledge Commission's studies, which show that around 76.4% of Indian pharma companies have introduced incremental pharma innovation in recent years while only 37% of them have been able to manage breakthrough innovation, USIBC makes a case for patent regime, which doesn’t entail wholesale exclusion of patent based on modifications, new dosing, new delivery system, the most common forms of incremental pharma innovations.
Further, the USIBC projects that by 2015, the share of incremental pharma market would account for $7 billion, almost 30% of the total pie of $20 billion Indian pharma market.
Traditionally, the government, the policy makers and the judiciary have not favoured grant of patent to incremental pharma innovations.
-
Expanding the scope of India’s current patent regime to include incremental pharma innovation would benefit the domestic pharma players, according to a study commissioned by the US India Business Council, which was released on Wednesday.
Citing statistics from the National Knowledge Commission's studies, which show that around 76.4% of Indian pharma companies have introduced incremental pharma innovation in recent years while only 37% of them have been able to manage breakthrough innovation, USIBC makes a case for patent regime, which doesn’t entail wholesale exclusion of patent based on modifications, new dosing, new delivery system, the most common forms of incremental pharma innovations.
Further, the USIBC projects that by 2015, the share of incremental pharma market would account for $7 billion, almost 30% of the total pie of $20 billion Indian pharma market.
Traditionally, the government, the policy makers and the judiciary have not favoured grant of patent to incremental pharma innovations.
This link has been bookmarked by 1 people . It was first bookmarked on 27 Aug 2009, by gibreel ferishta.
-
gibreel ferishta
Expanding the scope of India’s current patent regime to include incremental pharma innovation would benefit the domestic pharma players, according to a study commissioned by the US India Business Council, which was released on Wednesday.
Citing statistics from the National Knowledge Commission's studies, which show that around 76.4% of Indian pharma companies have introduced incremental pharma innovation in recent years while only 37% of them have been able to manage breakthrough innovation, USIBC makes a case for patent regime, which doesn’t entail wholesale exclusion of patent based on modifications, new dosing, new delivery system, the most common forms of incremental pharma innovations.
Further, the USIBC projects that by 2015, the share of incremental pharma market would account for $7 billion, almost 30% of the total pie of $20 billion Indian pharma market.
Traditionally, the government, the policy makers and the judiciary have not favoured grant of patent to incremental pharma innovations.-
Expanding the scope of India’s current patent regime to include incremental pharma innovation would benefit the domestic pharma players, according to a study commissioned by the US India Business Council, which was released on Wednesday.
Citing statistics from the National Knowledge Commission's studies, which show that around 76.4% of Indian pharma companies have introduced incremental pharma innovation in recent years while only 37% of them have been able to manage breakthrough innovation, USIBC makes a case for patent regime, which doesn’t entail wholesale exclusion of patent based on modifications, new dosing, new delivery system, the most common forms of incremental pharma innovations.
Further, the USIBC projects that by 2015, the share of incremental pharma market would account for $7 billion, almost 30% of the total pie of $20 billion Indian pharma market.
Traditionally, the government, the policy makers and the judiciary have not favoured grant of patent to incremental pharma innovations.
-
Would you like to comment?
Join Diigo for a free account, or sign in if you are already a member.